New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL

Abstract CD19‐directed chimeric antigen receptor T‐cell therapy (CAR‐T) represents a significant advancement for patients with relapsed/refractory large B‐cell lymphoma (LBCL). Long‐term follow‐up confirms durable remissions in nearly half of the patients, a population that was previously estimated...

Full description

Bibliographic Details

Published in:	eJHaem
Main Authors:	Madiha Iqbal, Bipin N Savani, Mehdi Hamadani
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Subjects:	allogeneic CAR CAR‐T dual CAR follicular lymphoma lymphoma mantle cell
Online Access:	https://doi.org/10.1002/jha2.323